Question explored with the scientific record
Amlodipine
Amlodipine lowers blood pressure reliably. Whether that translates into living longer or avoiding a heart attack is a different question, and the retrieved evidence does not settle it.
Amlodipine is a long-acting calcium channel blocker used for high blood pressure and chest pain from narrowed heart arteries. It works by relaxing blood vessel walls, and it does lower pressure: in one trial of stroke patients it dropped systolic pressure from about 167 to 143 mmHg [1], and in another it cut systolic pressure by roughly 27 mmHg with no rise in heart rate [7]. For stable angina, a single 10 mg dose extended exercise time from about 299 to 368 seconds and pushed back the onset of ST-segment depression on a treadmill test [3].
The evidence here is mostly surrogate endpoints: blood pressure numbers, exercise time, pulse wave velocity. Those are lab and test readouts, not heart attacks or deaths. The one place hard outcomes appear is a review of older trials pooling about 8,700 patients on calcium channel blockers versus 8,500 controls, showing a relative risk of death of 0.85 favoring the drugs [5]. That is a pooled number from studies of varying quality, and it is the strongest outcome evidence in this retrieval.
| Comparison | Amlodipine | Comparator |
|---|---|---|
| Adverse events vs lercanidipine [1] | 19.2% | 5.7% |
| Peripheral edema vs ivabradine [4] | 7.9% | 1.3% |
| Edema, combo vs amlodipine alone [6] | 18.7% | 7.6% |
| Response rate, stroke patients [1] | 44.2% | 36.5% |
The main cost is ankle swelling, which runs higher on amlodipine than on several alternatives [1][4][6]. In the elderly, amlodipine clears more slowly and produces more pressure drop at the same blood level, so dose matters more in that group [2]. Nothing in this retrieval reports long-term safety data, cancer, or all-cause mortality for amlodipine specifically, and no study here compared amlodipine to a genuinely untreated group over years. That comparison is the one that would answer whether the drug changes how long you live, and it is not in these records.
My call: amlodipine is a real blood pressure drug with a modest, well-documented edema cost, and the hard-outcome benefit is suggested but not proven by this evidence. Confidence: moderate for blood pressure lowering, low for long-term outcome benefit.
Sources used 7
-
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke
This study compares the efficacy and safety of lercanidipine and amlodipine in treating hypertensive patients with acute cerebral ischemic stroke, finding that both drugs effectively reduce blood pressure but lercanidipine has a better safety profile.
DOI: 10.1185/03007995.2014.964855 -
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition
This study investigates the pharmacodynamics and disposition of amlodipine, a calcium antagonist, in elderly versus young hypertensive patients, revealing that elderly patients experience prolonged drug elimination and greater blood pressure reduction at equivalent plasma concen…
DOI: 10.1038/clpt.1990.120 -
Antianginal effects of amlodipine at a single dose on exertional angina patients using treadmill exercise testing?A randomized crossover study in comparison with placebo
This study evaluates the antianginal effects of a single 10 mg dose of amlodipine in patients with stable exertional angina, demonstrating significant improvements in exercise tolerance and ST-segment depression compared to placebo over a 24-hour period.
DOI: 10.1007/BF00055605 -
Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina Pectoris
This study demonstrates that ivabradine is as effective as amlodipine in improving exercise tolerance and has a comparable safety profile in patients with stable effort angina pectoris over a three-month period.
DOI: 10.2165/00003495-200767030-00005 -
First line drugs in chronic stable effort angina—the case for newer, longer-acting calcium channel blocking agents
This article reevaluates evidence on first-line calcium channel blockers versus beta-blockers for chronic stable exertional angina, arguing that newer long-acting CCBs offer at least equivalent antianginal efficacy with favorable tolerability and potential mortality benefits, pr…
DOI: 10.1016/s0735-1097(00)00946-3 -
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study
This study evaluates the efficacy and tolerability of a fixed-dose combination of amlodipine and ramipril compared to amlodipine monotherapy in patients with essential hypertension over an 18-week period, finding that the combination therapy significantly reduces blood pressure …
DOI: 10.1016/j.clinthera.2008.09.008 -
Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment
A study employing invasive central hemodynamic measurements and 24-hour ambulatory blood pressure monitoring in hypertensive patients to evaluate the long-term hemodynamic effects and 24-hour BP control of amlodipine, demonstrating reduced total peripheral resistance without adv…
DOI: 10.1016/0002-9149(94)90274-7